Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -78.68
- Piotroski Score 3.00
- Grade Buy
- Symbol (MBIO)
- Company Mustang Bio, Inc.
- Price $0.23
- Changes Percentage (-3.73%)
- Change -$0.01
- Day Low $0.23
- Day High $0.26
- Year High $2.13
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$4.40
- Trailing P/E Ratio -0.03
- Forward P/E Ratio -0.03
- P/E Growth -0.03
- Net Income $-51,602,000
Income Statement
Quarterly
Annual
Latest News of MBIO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Alex Hall and Nik Richie toast to Cymbiotika co-founder Durana Elmi's cover
Newsweek's entertainment gossip features a glamorous event at The Mayor's Table in Newport Beach celebrating Durana Elmi's magazine cover debut. Notable guests included Alex Hall and NFL quarterback M...
By Newsweek | 1 month ago -
Mustang Bio, Inc. (MBIO) Stock Price, News, Quote & History
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focusing on developing cell and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases....
By Yahoo! Finance | 3 months ago -
Mustang Bio, Inc. (MBIO) Stock Price, News, Quote & History - Yahoo Finance
Mustang Bio reports positive results from Phase 1/2 trial of MB-106 CAR-T therapy for Waldenstrom Macroglobulinemia. 90% response rate with durable responses, including one patient in remission at 31 ...
By Yahoo! Finance | 3 months ago
